OR2T33

Across TCGA pan-cancer cohorts, OR2T33 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated OR2T33 data layer compared with 12 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher OR2T33 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated OR2T33 expression acts as an unfavorable survival marker.

ESCA, STAD, and LUSC are the cancer types where OR2T33 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	DFS	Median	All	0.153	0.541	<.001	24	view →
STAD	DFS	Median	II,III,IV	0.121	0.618	<.001	15	view →
LUSC	OS	Median	III,IV	0.190	0.581	.002	13	view →
ACC	OS	Median	All	0.188	0.820	<.001	12	view →
BLCA	OS	Median	III,IV	0.535	0.655	.020	6	view →
UCEC	OS	Median	IV	0.232	0.608	.006	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

OR2T33–ESCA (DFS)

Open the ESCA breakdown →